Paroxetine for the treatment of depression: A critical update

Expert Opinion on Pharmacotherapy

Volumn 13, Issue 3, 2012, Pages 421-431

  Gibiino, Sara ^a   Serretti, Alessandro ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Antidepressant; Depression; Paroxetine; Specificity

Indexed keywords

FLUOXETINE; MIRTAZAPINE; PAROXETINE;

ARTICLE; ASTHENIA; BODY WEIGHT; CONSTIPATION; CONTROLLED CLINICAL TRIAL (TOPIC); DECREASED APPETITE; DEPRESSION; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG INFORMATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EJACULATION DISORDER; GYNECOLOGIC DISEASE; HUMAN; IMPOTENCE; INJURY; INSOMNIA; LIBIDO DISORDER; MALE GENITAL SYSTEM DISEASE; NAUSEA; NERVOUSNESS; PRESCRIPTION; SEXUAL DYSFUNCTION; SEXUAL FUNCTION; SIDE EFFECT; SOMNOLENCE; SWEATING; TREMOR; VISUAL DISORDER; WEIGHT GAIN; WITHDRAWAL SYNDROME; YAWNING;

ANIMALS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; DEPRESSION; EVIDENCE-BASED MEDICINE; HUMANS; PAROXETINE; PATIENT SELECTION; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 84856272650     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2012.652085     Document Type: Article

References (106)

1. Murray CJL, Lopez AD. The global burden of disease and injury series, volume 1: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Harvard University Press; Cambridge, MA: 1996
2. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). Jama 2003;289(23):3095-105 (Pubitemid 37432885)
3. Pae CU, Misra A, Ham BJ, et al. Paroxetine mesylate: comparable to paroxetine hydrochloride? Expert Opin Pharmacother 2010;11(2):185-93
4. Kennedy SH, Young AH, Blier P. Strategies to achieve clinical effectiveness: Refining existing therapies and pursuing emerging targets. J Affect Disord 2011;132(Suppl 1):S21-8
5. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 2009;373(9665):746-58
6. Agius M, Gardner J, Liu K, et al. Was Cipriani right? Audits to compare discharge rates and suicidality between antidepressant monotherapies used in a British community mental health team. Psychiatr Danub 2010;22(Suppl 1):S46-8
7. Gartlehner G, Hansen RA. Are some antidepressants better than others? Nat Rev Neurol 2009;5(5):239-40
8. Klemp M, Tvete IF, Gasemyr J, et al. Meta-regression analysis of paroxetine clinical trial data: does reporting scale matter? J Clin Psychopharmacol 2011;31(2):201-6
9. Serretti A, Gibiino S, Drago A. Specificity profile of paroxetine in major depressive disorder: meta-regression of double-blind, randomized clinical trials. J Affect Disord 2011;132(1-2):14-25
10. Impact of Generics on the Antidepressant Market. Available from: http://www. researchandmarkets.com/reports/314820 [Cited 25 August 2011]
11. Rosenthal J, Kong B, Jacobs L, et al. Did a switch to a generic antidepressant cause relapse? J Fam Pract 2008;57(2):109-14 (Pubitemid 351272498)
12. Bang LM, Keating GM. Paroxetine controlled release. CNS Drugs 2004;18(6):355-64; discussion 65-6 (Pubitemid 38621683)
13. Pae CU, Bahk WM, Jon DI, et al. Effectiveness and tolerability of paroxetine controlled release (CR) in the treatment of major depressive disorder: an open-label, prospective, multi-center trial in Korea. Hum Psychopharmacol 2007;22(6):351-9
14. Nielsen M, Gotzsche P. An analysis of psychotropic drug sales. Increasing sales of selective serotonin reuptake inhibitors are closely related to number of products. Int J Risk Saf Med 2011;23(2):125-32
15. Turner EH, Matthews AM, Linardatos E, et al. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med 2008;358(3):252-60
16. Fournier JC, DeRubeis RJ, Hollon SD, et al. Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA 2010;303(1):47-53
17. Chen J, Rizzo JA. Racial and ethnic disparities in antidepressant drug use. J Ment Health Policy Econ 2008;11(4):155-65
18. Gaskin DJ, Briesacher BA, Limcangco R, et al. Exploring racial and ethnic disparities in prescription drug spending and use among Medicare beneficiaries. Am J Geriatr Pharmacother 2006;4(2):96-111 (Pubitemid 44069475)
19. Golden RN, Nemeroff CB, McSorley P, et al. Efficacy and tolerability of controlled-release and immediate-release paroxetine in the treatment of depression. J Clin Psychiatry 2002;63(7):577-84 (Pubitemid 34787322)
20. FDA: paroxetine. Available from: http://www.accessdata.fda.gov/scripts/ cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&SearchTerm= paroxetine&SearchType=BasicSearch&-totable [Cited 20 August 2011]
21. Thase ME. Managing depressive and anxiety disorders with escitalopram. Expert Opin Pharmacother 2006;7(4):429-40 (Pubitemid 43379609)
22. Owens MJ, Knight DL. Human monamine transporter binding profile of SSRIs [New Research abstracts]. American Psychiatric Association 2000 Annual meeting: the doctor-patient relationship; 13 May 2000; Chicago; 2000. p. 144-5
23. Thomas DR, Nelson DR, Johnson AM. Biochemical effects of the antidepressant paroxetine, a specific 5-hydroxytryptamine uptake inhibitor. Psychopharmacology (Berl) 1987;93(2):193-200 (Pubitemid 18013056)
24. Owens MJ, Krulewicz S, Simon JS, et al. Estimates of serotonin and norepinephrine transporter inhibition in depressed patients treated with paroxetine or venlafaxine. Neuropsychopharmacology 2008;33(13):3201-12
25. Owens MJ, Morgan WN, Plott SJ, et al. Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J Pharmacol Exp Ther 1997;283(3):1305-22 (Pubitemid 28016506)
26. Owens MJ, Knight DL, Nemeroff CB. Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol Psychiatry 2001;50(5):345-50 (Pubitemid 32816947)
27. Nemeroff CB, Owens MJ. Treatment of mood disorders. Nat Neurosci 2002;5(Suppl):1068-70 (Pubitemid 35247201)
28. Bourin M, Chue P, Guillon Y. Paroxetine: a review. CNS Drug Rev 2001;7(1):25-47 (Pubitemid 32280682)
29. Kaye CM, Haddock RE, Langley PF, et al. A review of the metabolism and pharmacokinetics of paroxetine in man. Acta Psychiatr Scand Suppl 1989;350:60-75 (Pubitemid 19236643)
30. Duboff EA. Long-term treatment of major depressive disorder with paroxetine. J Clin Psychopharmacol 1993;13(6 Suppl 2):28S-33S (Pubitemid 24025199)
31. Lundmark J, Bengtsson F, Nordin C, et al. Therapeutic drug monitoring of selective serotonin reuptake inhibitors influences clinical dosing strategies and reduces drug costs in depressed elderly patients. Acta Psychiatr Scand 2000;101(5):354-9 (Pubitemid 30233000)
32. Porcelli S, Drago A, Fabbri C, et al. Pharmacogenetics of antidepressant response. J Psychiatry Neurosci 2011;36(2):87-113
33. Mahgoub A, Idle JR, Dring LG, et al. Polymorphic hydroxylation of Debrisoquine in man. Lancet 1977;2(8038):584-6 (Pubitemid 8176607)
34. Eichelbaum M, Spannbrucker N, Steincke B, et al. Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur J Clin Pharmacol 1979;16(3):183-7 (Pubitemid 10194487)
35. Zanger UM, Raimundo S, Eichelbaum M. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol 2004;369(1):23-37 (Pubitemid 38161221)
36. Doran A, Obach RS, Smith BJ, et al. The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model. Drug Metab Dispos 2005;33(1):165-74 (Pubitemid 40023528)
37. Uhr M, Grauer MT, Holsboer F. Differential enhancement of antidepressant penetration into the brain in mice with abcb1ab (mdr1ab) P-glycoprotein gene disruption. Biol Psychiatry 2003;54(8):840-6 (Pubitemid 37205136)
38. Weiss J, Dormann SM, Martin-Facklam M, et al. Inhibition of P-glycoprotein by newer antidepressants. J Pharmacol Exp Ther 2003;305(1):197-204 (Pubitemid 36373851)
39. Yasui-Furukori N, Kaneko S. Digitalis intoxication induced by paroxetine co-administration. Lancet 2006;367(9512):788 (Pubitemid 43326297)
40. Yasui-Furukori N, Saito M, Niioka T, et al. Effect of itraconazole on pharmacokinetics of paroxetine: the role of gut transporters. Ther Drug Monit 2007;29(1):45-8 (Pubitemid 46279875)
41. Gex-Fabry M, Eap CB, Oneda B, et al. CYP2D6 and ABCB1 genetic variability: influence on paroxetine plasma level and therapeutic response. Ther Drug Monit 2008;30(4):474-82
42. Mihaljevic Peles A, Bozina N, Sagud M, et al. MDR1 gene polymorphism: therapeutic response to paroxetine among patients with major depression. Prog Neuropsychopharmacol Biol Psychiatry 2008;32(6):1439-44
43. Wagstaff AJ, Cheer SM, Matheson AJ, et al. Paroxetine: an update of its use in psychiatric disorders in adults. Drugs 2002;62(4):655-703 (Pubitemid 34264033)
44. Katzman MA, Tricco AC, McIntosh D, et al. Paroxetine versus placebo and other agents for depressive disorders: a systematic review and meta-analysis. J Clin Psychiatry 2007;68(12):1845-59
45. Gartlehner G, Hansen RA, Thieda P, et al. Comparative Effectiveness of Second-Generation Antidepressants in the Pharmacologic Treatment of Adult Depression. Comparative Effectiveness Review No. 7. 2010/08/13 ed. Agency for Healthcare Research and Quality; Rockville, MD: 2007
46. Schone W, Ludwig M. A double-blind study of paroxetine compared with fluoxetine in geriatric patients with major depression. J Clin Psychopharmacol 1993;13(6 Suppl 2):34S-9S (Pubitemid 24025200)
47. Geretsegger C, Bohmer F, Ludwig M. Paroxetine in the elderly depressed patient: randomized comparison with fluoxetine of efficacy, cognitive and behavioural effects. Int Clin Psychopharmacol 1994;9(1):25-9 (Pubitemid 24062648)
48. Kroenke K, West SL, Swindle R, et al. Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: a randomized trial. JAMA 2001;286(23):2947-55 (Pubitemid 33140358)
49. Cassano GB, Puca F, Scapicchio PL, et al. Paroxetine and fluoxetine effects on mood and cognitive functions in depressed nondemented elderly patients. J Clin Psychiatry 2002;63(5):396-402 (Pubitemid 34507216)
50. Schatzberg AF, Kremer C, Rodrigues HE, et al. Double-blind, randomized comparison of mirtazapine and paroxetine in elderly depressed patients. Am J Geriatr Psychiatry 2002;10(5):541-50 (Pubitemid 34984390)
51. Rapaport MH, Lydiard RB, Pitts CD, et al. Low doses of controlled-release paroxetine in the treatment of late-life depression: a randomized, placebo-controlled trial. J Clin Psychiatry 2009;70(1):46-57
52. Rapaport MH, Schneider LS, Dunner DL, et al. Efficacy of controlled-release paroxetine in the treatment of late-life depression. J Clin Psychiatry 2003;64(9):1065-74 (Pubitemid 37158252)
53. Thase ME, Entsuah R, Cantillon M, et al. Relative antidepressant efficacy of venlafaxine and SSRIs: sex-age interactions. J Womens Health (Larchmt) 2005;14(7):609-16 (Pubitemid 41488679)
54. Eaton WW, Anthony JC, Gallo J, et al. Natural history of Diagnostic Interview Schedule/DSM-IV major depression. The baltimore epidemiologic catchment area follow-up. Arch Gen Psychiatry 1997;54(11):993-9 (Pubitemid 27476094)
55. Ehde DM, Kraft GH, Chwastiak L, et al. Efficacy of paroxetine in treating major depressive disorder in persons with multiple sclerosis. Gen Hosp Psychiatry 2008;30(1):40-8 (Pubitemid 350299496)
56. Menza M, Dobkin RD, Marin H, et al. A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology 2009;72(10):886-92
57. Wermuth L, Sorensen PS, Timm S, et al. Depression in idiopathic Parkinson's disease treated with paroxetine: a placebo-controlled trial. Nord J Psychiatry 1998;52:163-9 (Pubitemid 28310706)
58. Ceravolo R, Nuti A, Piccinni A, et al. Paroxetine in Parkinson's disease: effects on motor and depressive symptoms. Neurology 2000;55(8):1216-18
59. Clark LA, Watson D, Mineka S. Temperament, personality, and the mood and anxiety disorders. J Abnorm Psychol 1994;103(1):103-16 (Pubitemid 24066960)
60. Du L, Bakish D, Ravindran AV, et al. Does fluoxetine influence major depression by modifying five-factor personality traits? J Affect Disord 2002;71(1-3):235-41
61. Gracious KS. Do SSRIs affect personality traits. Br J Psychiatry 1999;175:287
62. Marchevsky D. Selective serotonin reuptake inhibitors and personality change. Br J Psychiatry 1999;175:589-90
63. Tang TZ, DeRubeis RJ, Hollon SD, et al. Personality change during depression treatment: a placebo-controlled trial. Arch Gen Psychiatry 2009;66(12):1322-30
64. Tse WS, Bond AJ. Serotonergic involvement in the psychosocial dimension of personality. J Psychopharmacol 2001;15(3):195-8 (Pubitemid 32808254)
65. Knutson B, Wolkowitz OM, Cole SW, et al. Selective alteration of personality and social behavior by serotonergic intervention. Am J Psychiatry 1998;155(3):373-9 (Pubitemid 28114895)
66. Serretti A, Calati R, Goracci A, et al. Antidepressants in healthy subjects: what are the psychotropic/psychological effects? Eur Neuropsychopharmacol 2010;20(7):433-53
67. Kallen B, Otterblad Olausson P. Antidepressant drugs during pregnancy and infant congenital heart defect. Reprod Toxicol 2006;21(3):221-2 (Pubitemid 43294548)
68. Marks DM, Park MH, Ham BJ, et al. Paroxetine: safety and tolerability issues. Expert Opin Drug Saf 2008;7(6):783-94
69. Malm H, Artama M, Gissler M, et al. Selective serotonin reuptake inhibitors and risk for major congenital anomalies. Obstet Gynecol 2011;118(1):111-20
70. Sie SD, Wennink JM, van Driel JJ, et al. Maternal use of SSRIs, SNRIs and NaSSAs: practical recommendations during pregnancy and lactation. Arch Dis Child Fetal Neonatal Ed 2011 July 27: doi: 10.1136/adc.2011.214239
71. Reis M, Kallen B. Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data. Psychol Med 2010;40(10):1723-33
72. Berard A, Ramos E, Rey E, et al. First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage. Birth Defects Res B Dev Reprod Toxicol 2007;80(1):18-27
73. Sanz EJ, De-las-Cuevas C, Kiuru A, et al. Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis. Lancet 2005;365(9458):482-7 (Pubitemid 40215730)
74. Gentile S. SSRIs in pregnancy and lactation: emphasis on neurodevelopmental outcome. CNS Drugs 2005;19(7):623-33 (Pubitemid 41058372)
75. Gutman DA, Owens MJ. Serotonin and norepinephrine transporter binding profile of SSRIs. Essent Psychopharmacol 2006;7(1):35-41
76. Rahman M, Lax SF, Sutter CH, et al. CYP1B1 is not a major determinant of the disposition of aromatase inhibitors in epithelial cells of invasive ductal carcinoma. Drug Metab Dispos 2008;36(5):963-70 (Pubitemid 351574896)
77. Desmeules J, Gascon MP, Dayer P, et al. Impact of environmental and genetic factors on codeine analgesia. Eur J Clin Pharmacol 1991;41(1):23-6
78. Johnson MD, Zuo H, Lee KH, et al. Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res Treat 2004;85(2):151-9 (Pubitemid 38987269)
79. Price JS, Waller PC, Wood SM, et al. A comparison of the post-marketing safety of four selective serotonin re-uptake inhibitors including the investigation of symptoms occurring on withdrawal. Br J Clin Pharmacol 1996;42(6):757-63 (Pubitemid 26417618)
80. Coupland NJ, Bell CJ, Potokar JP. Serotonin reuptake inhibitor withdrawal. J Clin Psychopharmacol 1996;16(5):356-62 (Pubitemid 26352664)
81. Stahl MM, Lindquist M, Pettersson M, et al. Withdrawal reactions with selective serotonin re-uptake inhibitors as reported to the WHO system. Eur J Clin Pharmacol 1997;53(3-4):163-9 (Pubitemid 28018286)
82. Yasui-Furukori N, Kaneko S. Hallucination induced by paroxetine discontinuation in patients with major depressive disorders. Psychiatry Clin Neurosci 2011;65(4):384-5
83. Rodriguez-Pazos L, Gomez-Bernal S, Montero I, et al. Erythema multiforme photoinduced by paroxetine and herpes simplex virus. Photodermatol Photoimmunol Photomed 2011;27(4):219-21
84. Smith PF, Darlington CL. A possible explanation for dizziness following SSRI discontinuation. Acta Otolaryngol 2010;130(9):981-3
85. Himei A, Okamura T. Discontinuation syndrome associated with paroxetine in depressed patients: a retrospective analysis of factors involved in the occurrence of the syndrome. CNS Drugs 2006;20(8):665-72 (Pubitemid 44141493)
86. Blier P, Tremblay P. Physiologic mechanisms underlying the antidepressant discontinuation syndrome. J Clin Psychiatry 2006;67(Suppl 4):8-13 (Pubitemid 43764532)
87. Szabo ST, de Montigny C, Blier P. Modulation of noradrenergic neuronal firing by selective serotonin reuptake blockers. Br J Pharmacol 1999;126(3):568-71 (Pubitemid 29087832)
88. Papakostas GI. Tolerability of modern antidepressants. J Clin Psychiatry 2008;69(Suppl E1):8-13
89. Harvey BH, Bouwer CD. Neuropharmacology of paradoxic weight gain with selective serotonin reuptake inhibitors. Clin Neuropharmacol 2000;23(2):90-7 (Pubitemid 30212219)
90. Serretti A, Mandelli L. Antidepressants and body weight: a comprehensive review and meta-analysis. J Clin Psychiatry 2010;71(10):1259-72
91. Serretti A, Chiesa A. Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. J Clin Psychopharmacol 2009;29(3):259-66
92. Kennedy SH, Fulton KA, Bagby RM, et al. Sexual function during bupropion or paroxetine treatment of major depressive disorder. Can J Psychiatry 2006;51(4):234-42
93. Gartlehner G, Chapman A, Strobelberger M, et al. Differences in efficacy and safety of pharmaceutical treatments between men and women: an umbrella review. PLoS ONE 2010;5(7):e11895
94. Wagner KD. Paroxetine treatment of mood and anxiety disorders in children and adolescents. Psychopharmacol Bull 2003;37(Suppl 1):167-75
95. Carpenter DJ, Fong R, Kraus JE, et al. Meta-analysis of efficacy and treatmentemergent suicidality in adults by psychiatric indication and age subgroup following initiation of paroxetine therapy: a complete set of randomized placebo-controlled trials. J Clin Psychiatry 2011;72(11):1503-14
96. Kraus JE, Horrigan JP, Carpenter DJ, et al. Clinical features of patients with treatment-emergent suicidal behavior following initiation of paroxetine therapy. J Affect Disord 2010;120(1-3):40-7
97. Liu BA, Mittmann N, Knowles SR, et al. Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotonin reuptake inhibitors: a review of spontaneous reports. CMAJ 1996;155(5):519-27 (Pubitemid 26316956)
98. Jacob S, Spinler SA. Hyponatremia associated with selective serotonin-reuptake inhibitors in older adults. Ann Pharmacother 2006;40(9):1618-22 (Pubitemid 44330206)
99. Suwa A, Wakeno M, Tajika A, et al. Syndrome of inappropriate secretion of anti-diuretic hormone in an elderly depressive patient receiving paroxetine: a case report. Int J Geriatr Psychiatry 2010;25(4):433-4
100. Pergola PE, Sved AF, Voogt JL, et al. Effect of serotonin on vasopressin release: a comparison to corticosterone, prolactin and renin. Neuroendocrinology 1993;57(3):550-8 (Pubitemid 23170162)
101. Budman CL, Sherling M, Bruun RD. Combined pharmacotherapy risk. J Am Acad Child Adolesc Psychiatry 1995;34(3):263-4
102. Schneeweiss S, Patrick AR, Solomon DH, et al. Comparative safety of antidepressant agents for children and adolescents regarding suicidal acts. Pediatrics 2010;125(5):876-88
103. Zanardi R, Franchini L, Gasperini M, et al. Double-blind controlled trial of sertraline versus paroxetine in the treatment of delusional depression. Am J Psychiatry 1996;153(12):1631-3 (Pubitemid 26406178)
104. Kelly CM, Juurlink DN, Gomes T, et al. Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. Bmj 2010;340:c693
105. Cohn JB, Crowder JE, Wilcox CS, et al. A placebo- and imipramine-controlled study of paroxetine. Psychopharmacol Bull 1990;26(2):185-9 (Pubitemid 20291873)
106. Laursen AL, Mikkelsen PL, Rasmussen S, et al. Paroxetine in the treatment of depression-a randomized comparison with amitriptyline. Acta Psychiatr Scand 1985;71(3):249-55 (Pubitemid 15169900)